The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Authors: Abraham JE; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk., Pinilla K; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Dayimu A; Cambridge Cancer Trials Centre, University of Cambridge, Cambridge, UK., Grybowicz L; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Demiris N; Department of Statistics, Athens University of Economics and Business, Athens, Greece., Harvey C; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Drewett LM; Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK., Lucey R; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Fulton A; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Roberts AN; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Worley JR; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Chhabra A; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Qian W; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Vallier AL; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hardy RM; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Chan S; The City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK., Hickish T; Royal Bournemouth General Hospital, Bournemouth, UK., Tripathi D; Royal Wolverhampton NHS Trust, Wolverhampton, UK.; Russells Hall Hospital, Dudley, UK., Venkitaraman R; Ipswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK., Persic M; University Hospital of Derby and Burton, Derby, UK., Aslam S; Bedford Hospital, Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK., Glassman D; Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Wakefield, UK., Raj S; University Hospital Southampton NHS Foundation Trust, Southampton, UK.; Basingstoke & North Hampshire Hospital, Basingstoke, UK.; Royal Hampshire Hospital, Winchester, UK., Borley A; Velindre Cancer Centre, Cardiff, UK., Braybrooke JP; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Sutherland S; Mount Vernon Cancer Centre, Northwood, UK., Staples E; Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK., Scott LC; Beatson West Of Scotland Cancer Centre, Glasgow, UK., Davies M; Swansea Bay University Health Board, Swansea, UK., Palmer CA; Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, UK., Moody M; Macmillan Unit, West Suffolk Hospital NHS Foundation Trust, Bury Saint Edmunds, UK., Churn MJ; Worcestershire Acute Hospitals NHS Trust, Worcester, UK.; Alexandra Redditch Hospital, Redditch, UK.; Kidderminster Hospital, Kidderminster, Worcestershire, UK., Newby JC; Royal Free London NHS Foundation Trust, London, UK., Mukesh MB; Oncology Department, Colchester General Hospital, East Suffolk & North Essex NHS Trust, Colchester, UK., Chakrabarti A; University Hospitals Dorset NHS Foundation Trust, Poole, UK., Roylance RR; University College London Hospitals NHS Foundation Trust, London, UK., Schouten PC; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Levitt NC; Oxford University Hospital NHS Foundation Trust, Oxford, UK., McAdam K; Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK., Armstrong AC; The Christie NHS Foundation Trust and Division of Cancer Sciences, Manchester, UK., Copson ER; Cancer Sciences Academic Unit, University of Southampton, Southampton, UK., McMurtry E; EMC2 Clinical Consultancy, Sale, Manchester, UK., Tischkowitz M; Department of Medical Genetics, National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Provenzano E; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Earl HM; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.
Source: Nature [Nature] 2024 May; Vol. 629 (8014), pp. 1142-1148. Date of Electronic Publication: 2024 Apr 08.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Clinical Trial, Phase III
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-4687
DOI:10.1038/s41586-024-07384-2